Cargando…

Lower airway microbiota and decreasing lung function in young Brazilian cystic fibrosis patients with pulmonary Staphylococcus and Pseudomonas infection

Cystic fibrosis (CF) is a genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator gene that leads to respiratory complications and mortality. Studies have shown shifts in the respiratory microbiota during disease progression in individuals with CF. In addition,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kussek, Paulo, Mesa, Dany, Vasconcelos, Thaís Muniz, Rodrigues, Luiza Souza, Krul, Damaris, Ibanez, Humberto, Faoro, Helisson, Palmeiro, Jussara Kasuko, Dalla Costa, Libera Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409528/
https://www.ncbi.nlm.nih.gov/pubmed/36006942
http://dx.doi.org/10.1371/journal.pone.0273453
_version_ 1784774873124438016
author Kussek, Paulo
Mesa, Dany
Vasconcelos, Thaís Muniz
Rodrigues, Luiza Souza
Krul, Damaris
Ibanez, Humberto
Faoro, Helisson
Palmeiro, Jussara Kasuko
Dalla Costa, Libera Maria
author_facet Kussek, Paulo
Mesa, Dany
Vasconcelos, Thaís Muniz
Rodrigues, Luiza Souza
Krul, Damaris
Ibanez, Humberto
Faoro, Helisson
Palmeiro, Jussara Kasuko
Dalla Costa, Libera Maria
author_sort Kussek, Paulo
collection PubMed
description Cystic fibrosis (CF) is a genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator gene that leads to respiratory complications and mortality. Studies have shown shifts in the respiratory microbiota during disease progression in individuals with CF. In addition, CF patients experience short cycles of acute intermittent aggravations of symptoms called pulmonary exacerbations, which may be characterized by a decrease in lung function and weight loss. The resident microbiota become imbalanced, promoting biofilm formation, and reducing the effectiveness of therapy. The aim of this study was to monitor patients aged 8–23 years with CF to evaluate their lower respiratory microbiota using 16S rRNA sequencing. The most predominant pathogens observed in microbiota, Staphylococcus (Staph) and Pseudomonas (Pseud) were correlated with clinical variables, and the in vitro capacity of biofilm formation for these pathogens was tested. A group of 34 patients was followed up for 84 days, and 306 sputum samples were collected and sequenced. Clustering of microbiota by predominant pathogen showed that children with more Staph had reduced forced expiratory volume in one second (FEV(1)) and forced vital capacity (FVC) compared to children with Pseud. Furthermore, the patients’ clinical condition was consistent with the results of pulmonary function. More patients with pulmonary exacerbation were observed in the Staph group than in the Pseud group, as confirmed by lower body mass index and pulmonary function. Additionally, prediction of bacterial functional profiles identified genes encoding key enzymes involved in virulence pathways in the Pseud group. Importantly, this study is the first Brazilian study to assess the lower respiratory microbiota in a significant group of young CF patients. In this sense, the data collected for this study on the microbiota of children in Brazil with CF provide a valuable contribution to the knowledge in the field.
format Online
Article
Text
id pubmed-9409528
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-94095282022-08-26 Lower airway microbiota and decreasing lung function in young Brazilian cystic fibrosis patients with pulmonary Staphylococcus and Pseudomonas infection Kussek, Paulo Mesa, Dany Vasconcelos, Thaís Muniz Rodrigues, Luiza Souza Krul, Damaris Ibanez, Humberto Faoro, Helisson Palmeiro, Jussara Kasuko Dalla Costa, Libera Maria PLoS One Research Article Cystic fibrosis (CF) is a genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator gene that leads to respiratory complications and mortality. Studies have shown shifts in the respiratory microbiota during disease progression in individuals with CF. In addition, CF patients experience short cycles of acute intermittent aggravations of symptoms called pulmonary exacerbations, which may be characterized by a decrease in lung function and weight loss. The resident microbiota become imbalanced, promoting biofilm formation, and reducing the effectiveness of therapy. The aim of this study was to monitor patients aged 8–23 years with CF to evaluate their lower respiratory microbiota using 16S rRNA sequencing. The most predominant pathogens observed in microbiota, Staphylococcus (Staph) and Pseudomonas (Pseud) were correlated with clinical variables, and the in vitro capacity of biofilm formation for these pathogens was tested. A group of 34 patients was followed up for 84 days, and 306 sputum samples were collected and sequenced. Clustering of microbiota by predominant pathogen showed that children with more Staph had reduced forced expiratory volume in one second (FEV(1)) and forced vital capacity (FVC) compared to children with Pseud. Furthermore, the patients’ clinical condition was consistent with the results of pulmonary function. More patients with pulmonary exacerbation were observed in the Staph group than in the Pseud group, as confirmed by lower body mass index and pulmonary function. Additionally, prediction of bacterial functional profiles identified genes encoding key enzymes involved in virulence pathways in the Pseud group. Importantly, this study is the first Brazilian study to assess the lower respiratory microbiota in a significant group of young CF patients. In this sense, the data collected for this study on the microbiota of children in Brazil with CF provide a valuable contribution to the knowledge in the field. Public Library of Science 2022-08-25 /pmc/articles/PMC9409528/ /pubmed/36006942 http://dx.doi.org/10.1371/journal.pone.0273453 Text en © 2022 Kussek et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Kussek, Paulo
Mesa, Dany
Vasconcelos, Thaís Muniz
Rodrigues, Luiza Souza
Krul, Damaris
Ibanez, Humberto
Faoro, Helisson
Palmeiro, Jussara Kasuko
Dalla Costa, Libera Maria
Lower airway microbiota and decreasing lung function in young Brazilian cystic fibrosis patients with pulmonary Staphylococcus and Pseudomonas infection
title Lower airway microbiota and decreasing lung function in young Brazilian cystic fibrosis patients with pulmonary Staphylococcus and Pseudomonas infection
title_full Lower airway microbiota and decreasing lung function in young Brazilian cystic fibrosis patients with pulmonary Staphylococcus and Pseudomonas infection
title_fullStr Lower airway microbiota and decreasing lung function in young Brazilian cystic fibrosis patients with pulmonary Staphylococcus and Pseudomonas infection
title_full_unstemmed Lower airway microbiota and decreasing lung function in young Brazilian cystic fibrosis patients with pulmonary Staphylococcus and Pseudomonas infection
title_short Lower airway microbiota and decreasing lung function in young Brazilian cystic fibrosis patients with pulmonary Staphylococcus and Pseudomonas infection
title_sort lower airway microbiota and decreasing lung function in young brazilian cystic fibrosis patients with pulmonary staphylococcus and pseudomonas infection
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409528/
https://www.ncbi.nlm.nih.gov/pubmed/36006942
http://dx.doi.org/10.1371/journal.pone.0273453
work_keys_str_mv AT kussekpaulo lowerairwaymicrobiotaanddecreasinglungfunctioninyoungbraziliancysticfibrosispatientswithpulmonarystaphylococcusandpseudomonasinfection
AT mesadany lowerairwaymicrobiotaanddecreasinglungfunctioninyoungbraziliancysticfibrosispatientswithpulmonarystaphylococcusandpseudomonasinfection
AT vasconcelosthaismuniz lowerairwaymicrobiotaanddecreasinglungfunctioninyoungbraziliancysticfibrosispatientswithpulmonarystaphylococcusandpseudomonasinfection
AT rodriguesluizasouza lowerairwaymicrobiotaanddecreasinglungfunctioninyoungbraziliancysticfibrosispatientswithpulmonarystaphylococcusandpseudomonasinfection
AT kruldamaris lowerairwaymicrobiotaanddecreasinglungfunctioninyoungbraziliancysticfibrosispatientswithpulmonarystaphylococcusandpseudomonasinfection
AT ibanezhumberto lowerairwaymicrobiotaanddecreasinglungfunctioninyoungbraziliancysticfibrosispatientswithpulmonarystaphylococcusandpseudomonasinfection
AT faorohelisson lowerairwaymicrobiotaanddecreasinglungfunctioninyoungbraziliancysticfibrosispatientswithpulmonarystaphylococcusandpseudomonasinfection
AT palmeirojussarakasuko lowerairwaymicrobiotaanddecreasinglungfunctioninyoungbraziliancysticfibrosispatientswithpulmonarystaphylococcusandpseudomonasinfection
AT dallacostaliberamaria lowerairwaymicrobiotaanddecreasinglungfunctioninyoungbraziliancysticfibrosispatientswithpulmonarystaphylococcusandpseudomonasinfection